With his scientific publications, his incorporates both Cancer research and Melanoma. He connects Melanoma with Cancer research in his research. His research on Myeloid leukemia frequently links to adjacent areas such as Imatinib mesylate. His research on Imatinib mesylate often connects related topics like Myeloid leukemia. He performs integrative study on Imatinib and Targeted therapy. In his research, Christopher L. Corless undertakes multidisciplinary study on Targeted therapy and Imatinib. His Stromal cell study frequently draws parallels with other fields, such as Stromal tumor. His Pathology research extends to the thematically linked field of Stromal tumor. His PDGFRA research extends to the thematically linked field of Pathology.
Internal medicine and Surgery are two areas of study in which Christopher L. Corless engages in interdisciplinary research. He merges Surgery with Internal medicine in his study. He integrates Cancer research with Oncology in his study. He incorporates Oncology and Cancer research in his studies. With his scientific publications, his incorporates both Pathology and Immunohistochemistry. He performs multidisciplinary studies into Immunohistochemistry and Pathology in his work. His study in Stem cell extends to Genetics with its themes. His Stem cell study frequently intersects with other fields, such as Genetics. While working on this project, Christopher L. Corless studies both Cancer and Myeloid leukemia.
Christopher L. Corless performs multidisciplinary study in the fields of Cancer and Immunohistochemistry via his papers. His Immunohistochemistry study frequently draws parallels with other fields, such as Internal medicine. As part of his studies on Internal medicine, he often connects relevant areas like Metastasis. Christopher L. Corless merges Metastasis with Cancer in his research. His research on Genetics often connects related topics like Fibrosarcoma. The study of Fibrosarcoma is intertwined with the study of Genetics in a number of ways. Gene and Chromosome are two areas of study in which Christopher L. Corless engages in interdisciplinary research. He undertakes interdisciplinary study in the fields of Chromosome and Gene through his works. His work on Pathology is being expanded to include thematically relevant topics such as Sarcoma.
His work on Lung expands to the thematically related Internal medicine. His study connects Internal medicine and Lung. His multidisciplinary approach integrates Cancer and Adenocarcinoma in his work. His Genetics study frequently links to adjacent areas such as Mesenchymal stem cell. Christopher L. Corless integrates Mesenchymal stem cell and Stem cell in his research. The study of Stem cell is intertwined with the study of CD34 in a number of ways. In his works, Christopher L. Corless undertakes multidisciplinary study on Pathology and Precision medicine. Christopher L. Corless undertakes interdisciplinary study in the fields of Oncology and Gastroenterology through his works. Christopher L. Corless integrates Gastroenterology with Oncology in his research.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
George Daniel Demetri;Margaret von Mehren;Charles D. Blanke;Annick Diane Van Den Abbeele.
The New England Journal of Medicine (2002)
Diagnosis of gastrointestinal stromal tumors: A consensus approach.
Christopher D.M. Fletcher;Jules J. Berman;Christopher Corless;Fred Gorstein.
Human Pathology (2002)
PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
Michael C. Heinrich;Christopher L. Corless;Anette Duensing;Laura McGreevey.
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Michael C. Heinrich;Christopher L. Corless;George D. Demetri;Charles D. Blanke.
Journal of Clinical Oncology (2003)
Biology of gastrointestinal stromal tumors.
Christopher L. Corless;Jonathan A. Fletcher;Michael C. Heinrich.
Journal of Clinical Oncology (2004)
Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT
Charles D Blanke;George D Demetri;Margaret von Mehren;Michael C Heinrich.
Journal of Clinical Oncology (2008)
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.
George D. Demetri;Robert S. Benjamin;Charles D. Blanke;Jean Yves Blay.
Journal of The National Comprehensive Cancer Network (2007)
PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib
Christopher L. Corless;Arin Schroeder;Diana Griffith;Ajia Town.
Journal of Clinical Oncology (2005)
Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO
Jean Yves Blay;Sylvie Bonvalot;Paolo Casali;Haesun Choi.
Annals of Oncology (2005)
Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors
Michael C. Heinrich;Christopher L. Corless;Charles D. Blanke;George D. Demetri.
Journal of Clinical Oncology (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: